Publication: “Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations”

The publication preferred product characteristics (PPC) for therapeutic TB vaccines provides guidance to scientists, funding agencies, public and private sector organizations developing such vaccine candidates. It includes potential clinical end-points for evidence generation and discusses key considerations about potential clinical development strategies. You can read the article here.